Neurimmune is a clinical-stage biopharmaceutical company building next generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy.

Emerging Therapies

View all

Cardiomyopathy

Cliramitug:
The new path forward to the treatment of ATTR-CM

Alzheimer’s Disease

N101B3:
Designed for the brain. Built to clear amyloid.

Amyotrophic Lateral Sclerosis

AP-101:
Targeting misfolded SOD1 to change the course of ALS

View all

The "new" developments in this software line typically involve enhancements across four main pillars:

News

View all

Radixx11rce2 New -

The "new" developments in this software line typically involve enhancements across four main pillars:

13.01.2026

Alzheimer's Disease

Neurimmune today announced that the company joined the ACCESS-AD consortium, a new European initiative to accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management in real-world health systems.

07.01.2026

ALS

AL-S Pharma will present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15, 2026.

Screenshot of The New England Journal of Medicine webpage showing the article “Antibody NI006 for Depletion of Cardiac Amyloid” with cardiac tracer scan images.

N Engl J Med

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Cover of Science Translational Medicine (5 December 2018) showing an elderly man standing beside a large, gnarled tree.

Sci Transl Med.

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis

Nature

Emerging Therapies

News

Radixx11rce2 New -

Scientific Publications

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease